ClinicalTrials.gg
Not yet recruitingNCT07136558Updated Aug 22, 2025

Evaluation of ICP-B794 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ICP-B794 in Advanced Solid Tumors, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
410
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤75 years.
  2. confirmed other locally advanced or solid tumors.
  3. ≥3 months.
  4. Adequate organs function within 7 days prior to the first dose of ICP-B794
  5. Performance Status (ECOG PS) score of 0 or 1。
  6. At least one per V1.1 criteria.
  7. Able to provide archived tumor tissue sample (within 2 years) or fresh tumor tissue sample.
  8. Female participants of (WOCBP) must have a negative serum pregnancy test at screening.
  9. WOCBP and male participants must agree to use method.
  10. Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose of drug.
  11. Participants must be able to communicate effectively with investigators and comply with all study requirements.
  12. Participants voluntarily joined the study and signed the informed concent form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Other active primary within 3 years prior to the first dose of product.
  2. Prior or current treatment with the similar drug or related treatment specified in the protocol.
  3. Having a past medical history and unhealthy lifestyle history as specified in the protocol, or suffering from diseases as specified in the protocol.
  4. Toxicities from prior anti-tumor therapy not recovered to ≤ Grade 1 (per V5.0).
  5. Major arterial or venous thrombotic events within 3 months prior to first dose.
  6. Active bleeding within 2 months prior to screening or history of bleeding tendency.
  7. Major surgery within 28 days prior to first dose or minor surgery within 2 weeks prior to first dose.
  8. Requirement for systemic therapy within 14 days prior to first dose.
  9. History of severe , or known severe hypersensitivity to the active pharmaceutical ingredient, inactive ingredients in the drug product, or antibody-based drugs, or hypersensitivity to recombinant human or murine proteins, or history of severe infusion reaction.
  10. Administration of any within 4 weeks prior to first dose or history of hypersensitivity reactions of any grade.
  11. Female participants who are pregnant, lactating, or planning pregnancy during the study.
  12. Any psychiatric or cognitive disorder that may impair understanding or execution of the document and/or protocol compliance
  13. Other conditions determined by the investigator that render patients unsuitable for participation in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    ICP-B794

    Drug: ICP-B794

Interventions

  • DrugICP-B794

    Intravenous administration once every 3 weeks

06

What researchers measure

Primary outcomes

  1. Incidence, character, and severity of adverse events (AEs) as judged according to NCI-CTCAE v5.0

    Time frame: Up to 2 years

  2. Dose-limiting toxicities (DLT)

    Incidence, character, and severity of dose-limiting toxicities.

    Time frame: Up to 2 years

  3. The Recommended Dose (RD) of ICP-B794 for expansion and Maximum Tolerated Dose (MTD)

    Time frame: Up to 2 years

  4. Objective response rate (ORR)

    Time frame: Up to 2 years

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: Up to 2 years

  2. Time to Maximum Plasma Concentration (Tmax)

    Time frame: Up to 2 years

  3. Half-life (T1/2)

    Time frame: Up to 2 years

  4. Area under the concentration-time curve from zero time to infinity (AUC0-∞)

    Time frame: Up to 2 years

  5. Area under the concentration-time curve from zero time to the last measurable concentration time point t (AUC0-t)

    Time frame: Up to 2 years

  6. Apparent Clearance (CL/F)

    Time frame: Up to 2 years

  7. Terminal Apparent Volume of Distribution (Vz/F)

    Time frame: Up to 2 years

  8. Objective Response Rate (ORR)

    Time frame: Up to 2 years

  9. Disease control rate (DCR)

    Time frame: Up to 2 years

  10. Duration of response (DOR)

    Time frame: Up to 2 years

  11. Progression-Free Survival (PFS)

    Time frame: Up to 2 years

  12. Radiographic progression-free survival (rPFS)

    Time frame: Up to 2 years

  13. Overall survival (OS)

    Time frame: Up to 2 years

  14. Number of participants with anti-drug antibodies (ADA) to ICP-B794

    Time frame: Up to 2 years

Other outcomes

  1. B7-H3 protein expression

    Time frame: Up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Jun 2029, 46 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 22, 2025
StartEst.
Aug 2025
Primary completionEst.
Jun 2029
CompletionEst.
Dec 2030
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07136558
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 2025 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 22, 2025

Study contacts

Yilong Wu
Contact
syylwu@live.cn
13809775415
Yilong Wu
principal investigator · Guangdong Provincial People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion